015: Subtype Specific Stratification and Targeting of Pancreatic Adenocarcinoma

HIPO Investigator:

Prof. Andreas Trummp

Dr. Martin Sprick

Prof. Roland Eils

Prof. Wilko Weichert

Dr. Jens Werner


Supported by: HIPO/POP

Entity: Pancreatic Adenocarcinoma (PDAC)


Noll EM et al.; CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma, Nat. Med. 2016

Espinet E et al.; Cellular deconvolution and expression analysis of Stromal and Epithelial cells directly isolated from human Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatology 2017

DKFZ Logo 3zu Research en Black Blue sRGB

4c nctlogo 2009

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.